Relative Bioavailability, Safety, and Tolerability Following Subcutaneous Injection of Different Doses of BI 655130 and Different Injection Sites in Healthy Male and Female Subjects (a Single Dose, Mono-centric, Open-label Study in Matched-group Design)
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2019
Price : $35 *
At a glance
- Drugs Spesolimab (Primary)
- Indications Atopic dermatitis; Crohn's disease; Palmoplantar pustulosis; Pustular psoriasis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 06 Jun 2019 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Planned End Date changed from 27 May 2019 to 5 Jun 2019.
- 04 Jun 2019 Planned primary completion date changed from 27 May 2019 to 5 Jun 2019.